Abstract Library

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,

#4342 A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of unresectable, locally advanced or metastatic neuroendocrine neoplasms in China

Introduction: The incidence of NENs is on the rise. In NECs, research on surufatinib is still scarce.

Conference:

Presenting Author:

Authors: Liu S, Zhang L, Liu B, Liu Q,

Keywords: neuroendocrine neoplasm, surufatinib, neuroendocrine carcinoma, neuroendocrine tumour, real-world study,

#4223 US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Patients with NETs experience a range of comorbidities, and often present with carcinoid syndrome (CS).

Conference:

Presenting Author:

Authors: Chan J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Starr J,

Keywords: gastroenteropancreatic, neuroendocrine tumor, concomitant medication, burden,

#4035 The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

Introduction: Surufatinib (a small-molecule inhibitor of VEGFR1-3, FGFR1, and CSF-1R) has exhibited encouraging antitumor activity for the treatment of advanced neuroendocrine tumors (including NET and NEC) in multiple registration studies.

Conference:

Presenting Author: Jiang L

Authors: Jiang L, Chuntao W, Beiyuan H, Tao C, Haitao G,

Keywords: neuroendocrine tumor, real-world study, surufatinib,

#3949 Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,